Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy

Purpose: HER-2 is overexpressed in 20% to 30% of human breast cancer and is associated with poor outcome. Studies suggest an association between HER-2 overexpression and resistance to alkylating agents. To further evaluate th is relationship, we assessed the interaction of HER-2, measured by differen t methods, and outcome after dose intensification with alkylating agents in metastatic breast cancer. Patients and Methods: From 1988 to 1995 at Duke University, 425 patients wi th metastatic breast cancer were enrolled in a study of high-dose alkylatin g agents (HDC) with autologous cellular support after doxorubicin-based the rapy (AFM). HER-2 was measured in serum for shed extracellular domain (ECD) and in tissue by immunohistochemistry (IHC) and fluorescent in situ hybrid ization (FISH). Results: HER-2 ECD was positive in 29%(19 of 65) of patients pre-AFM and in 11.7% (34 of 290) pre-HDC. Higher pre-AFM and higher pre-HDC HER-2 ECD pre dicted worse overall survival (P =.045 and P =.0096, respectively). HER-2 o verexpression by IHC and FISH showed no correlation with worse disease-free survival or overall survival. FISH and ECD were highly specific for IHC (9 7.3% and 97.7% respectively). However, ECD had a low sensitivity for IHC- o nly 22% of patients with HER-2 in the primary tumor shed ECD into the serum . Conclusion: These data suggest that the method of measuring HER-2 is import ant in predicting clinical outcome. HER2 ECD may identify a poor prognosis subgroup of HER-2-positive tumors. Lack of association of HER2 by IHC/FISH with worse outcome suggests that therapy with AFM and/or HDC therapy may be able to overcome the effect of this prognostic factor or it may not be a p rognostic factor in this setting. (C) 2001 by American Society of Clinical Oncology.